BCLI Stock - Brainstorm Cell Therapeutics Inc.
Unlock GoAI Insights for BCLI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $849,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $849,000 | $-265,000 | $-285,000 | $-260,000 | $-219,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-11,693,000 | $-21,439,000 | $-24,822,000 | $-24,539,000 | $-31,684,000 |
| Net Income | $11.62M | $-17,192,000 | $-24,277,000 | $-24,457,000 | $-31,811,000 |
| Net Margin | 1369.0% | N/A | N/A | N/A | N/A |
| EPS | $2.19 | $-4.48 | $-9.93 | $-10.09 | $-14.09 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
BCLIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.35 | $-0.91 | -160.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.41 | $-0.34 | +17.1% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.97 | $-0.45 | +53.6% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.45 | $-1.80 | -300.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.60 | $-0.60 | 0.0% | = MET |
Q2 2024 | May 14, 2024 | $-1.05 | $-0.75 | +28.6% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-2.25 | $-1.65 | +26.7% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-2.10 | $-2.10 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-2.25 | $-1.95 | +13.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-2.40 | $-2.10 | +12.5% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-2.70 | $-2.10 | +22.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-2.25 | $-2.85 | -26.7% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-2.25 | $-2.85 | -26.7% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-1.95 | $-2.25 | -15.4% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-3.00 | $-2.55 | +15.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-3.15 | $-2.25 | +28.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-3.00 | $-2.55 | +15.0% | ✓ BEAT |
Q2 2021 | Apr 26, 2021 | $-4.05 | $-2.85 | +29.6% | ✓ BEAT |
Frequently Asked Questions about BCLI
What is BCLI's current stock price?
What is the analyst price target for BCLI?
What sector is Brainstorm Cell Therapeutics Inc. in?
What is BCLI's market cap?
Does BCLI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BCLI for comparison